Innoviva INVA
NASDAQ INVA
$21.33 -0.02 (-0.09%)
As of: Sep 4, 2026 · 3:59 PM EDT

Innoviva (INVA) Non Operating Investment Income (2020 - 2023)

Innoviva's (INVA) quarterly Non Operating Investment Income came in at $22.7 million in Q3 2023, up 355.52% YoY from $5.0 million in Q3 2022, and up 355.52% on a QoQ basis from -$8.9 million in Q3 2022.

Analysis

Innoviva (INVA) Non Operating Investment Income (2020 - 2023) Analysis & Trends

Innoviva (INVA) has 4 years of Non Operating Investment Income data on file, last reported at $22.7 million in Q3 2023.

  • Quarterly Non Operating Investment Income rose 355.52% year-over-year to $22.7 million in Q3 2023, while the trailing twelve-month figure through Sep 2023 was -$54.2 million (down 194.95% YoY) and the FY2024 annual result came in at -$5.3 million, down 120.83% from the prior year.
  • Non Operating Investment Income climbed to $22.7 million in Q3 2023, from -$8.9 million in the prior quarter.
  • In the past five years, Non Operating Investment Income ranged from a high of $134.0 million in Q3 2021 to a low of -$58.6 million in Q2 2022.
  • A 4-year average of $16.5 million and a median of $21.9 million in 2020 frame the typical range for Non Operating Investment Income.
  • Annual changes were most pronounced in 2021 — Non Operating Investment Income surged 556.19% — and 2022, when it tumbled 229.32%.
  • Tracing INVA's Non Operating Investment Income over 4 years: stood at -$38.1 million in 2020, then jumped by 451.65% to $134.0 million in 2021, then sank by 106.63% to -$8.9 million in 2022, then jumped by 355.52% to $22.7 million in 2023.
  • The last three Non Operating Investment Income figures came in at $22.7 million (Q3 2023), -$8.9 million (Q3 2022), and -$58.6 million (Q2 2022), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Investment Income (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn -
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn -
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn -
8 Royalty Pharma 28.45 Bn 27.61 Bn - -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn -
10 Innoviva 1.56 Bn 984.81 Mn 90.62 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2023 22.70 Mn
Sep 30, 2022 -67.88 Mn
Jun 30, 2022 -58.60 Mn
Mar 31, 2022 -9.41 Mn
Sep 30, 2021 133.97 Mn
Jun 30, 2021 45.32 Mn
Mar 31, 2021 55.05 Mn
Dec 31, 2020 11.03 Mn
Sep 30, 2020 -29.37 Mn
Jun 30, 2020 46.70 Mn
Mar 31, 2020 21.92 Mn